Skip to main content


Mikrobiomik is a biopharmaceutical company founded for the research, development, production and commercialization of biologic medicines based on the human microbiome.

At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently without therapeutic alternative such as non-alcoholic steatohepatitis.

Our first biologic medicine under investigation, MBK-01, aimed at treating intestinal infection caused by Clostridioides difficile, is in Phase III ongoing and is expected to be launched on the European market in the first half of 2025.


Our current shareholders, in addition to the founding partners, include:

  • Orza, a direct investment entity, belonging to the Elkarkidetza and Geroa pension funds.
  • Seed Capital Bizkaia, a public company attached to the Department of Economic Promotion of the Provincial Council of Bizkaia, which is strongly committed to fostering innovation, social impact and the promotion and regeneration of the entrepreneurial network in Bizkaia.
  • San Ignacio S.L, a “family office” specially oriented to support disruptive projects.



Mikrobiomik has started a new round of financing with a triple objective:

1) To launch in Europe our first investigational biologic medicine, MBK-01, currently in Phase III, and to accelerate the rest of the ongoing clinical trials.

2) To build a new GMP (Good Manufacturing Practices) manufacturing plant for industrial scale-up.

3) Triple our talent in the next 3 years.

Contact us: